These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 35963644)

  • 1. The comprehensive expression and functional analysis of m6A modification "readers" in hepatocellular carcinoma.
    Qin S; Liu G; Jin H; Chen X; He J; Xiao J; Qin Y; Mao Y; Zhao L
    Aging (Albany NY); 2022 Aug; 14(15):6269-6298. PubMed ID: 35963644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N6-methyladenosine with immune infiltration and PD-L1 in hepatocellular carcinoma: novel perspective to personalized diagnosis and treatment.
    Shi Y; Wang Y; Zhang W; Niu K; Mao X; Feng K; Zhang Y
    Front Endocrinol (Lausanne); 2023; 14():1153802. PubMed ID: 37469973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Dysregulation of SOX Family Correlates with DNA Methylation and Immune Microenvironment Characteristics to Predict Prognosis in Hepatocellular Carcinoma.
    Qin S; Liu G; Jin H; Chen X; He J; Xiao J; Qin Y; Mao Y; Zhao L
    Dis Markers; 2022; 2022():2676114. PubMed ID: 35465267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response.
    Jiang H; Ning G; Wang Y; Lv W
    Dis Markers; 2021; 2021():5576683. PubMed ID: 34221187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. YTH domain family: potential prognostic targets and immune-associated biomarkers in hepatocellular carcinoma.
    Liu M; Zhao Z; Cai Y; Bi P; Liang Q; Yan Y; Xu Z
    Aging (Albany NY); 2021 Nov; 13(21):24205-24218. PubMed ID: 34747720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic analysis of the expression profile and prognostic significance of m6A regulators and PD-L1 in hepatocellular carcinoma.
    Kong F; Wang K; Wang L
    Discov Oncol; 2022 Nov; 13(1):131. PubMed ID: 36434140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The potential role of RNA N6-methyladenosine in primary Sjögren's syndrome.
    Xiao Q; Wu X; Deng C; Zhao L; Peng L; Zhou J; Zhang W; Zhao Y; Fei Y
    Front Med (Lausanne); 2022; 9():959388. PubMed ID: 36465909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive analysis of N6-methyladenosine -related long non-coding RNAs and immune cell infiltration in hepatocellular carcinoma.
    Yu ZL; Zhu ZM
    Bioengineered; 2021 Dec; 12(1):1708-1724. PubMed ID: 33955330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The m6A/m5C/m1A Regulated Gene Signature Predicts the Prognosis and Correlates With the Immune Status of Hepatocellular Carcinoma.
    Li D; Li K; Zhang W; Yang KW; Mu DA; Jiang GJ; Shi RS; Ke D
    Front Immunol; 2022; 13():918140. PubMed ID: 35833147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. hnRNPA2B1 promotes the occurrence and progression of hepatocellular carcinoma by downregulating PCK1 mRNA via a m6A RNA methylation manner.
    Hao W; Chen Z; Tang J; Yang R; Gao WQ; Xu H
    J Transl Med; 2023 Nov; 21(1):861. PubMed ID: 38017546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. m6A-Related Genes Contribute to Poor Prognosis of Hepatocellular Carcinoma.
    Zou Y; Jiang G; Xie Y; Li H
    Comput Math Methods Med; 2022; 2022():2427987. PubMed ID: 36339682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. m6A modification of VEGFA mRNA by RBM15/YTHDF2/IGF2BP3 contributes to angiogenesis of hepatocellular carcinoma.
    Xu X; Wu S; Zhang Y; Fan W; Lin X; Chen K; Lin X
    Mol Carcinog; 2024 Nov; 63(11):2174-2189. PubMed ID: 39092767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. m6A Regulators Is Differently Expressed and Correlated With Immune Response of Esophageal Cancer.
    Zhao H; Xu Y; Xie Y; Zhang L; Gao M; Li S; Wang F
    Front Cell Dev Biol; 2021; 9():650023. PubMed ID: 33748145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression profiles and prognostic significance of RNA N6-methyladenosine-related genes in patients with hepatocellular carcinoma: evidence from independent datasets.
    Zhou Y; Yin Z; Hou B; Yu M; Chen R; Jin H; Jian Z
    Cancer Manag Res; 2019; 11():3921-3931. PubMed ID: 31118805
    [No Abstract]   [Full Text] [Related]  

  • 15. HBXIP drives metabolic reprogramming in hepatocellular carcinoma cells via METTL3-mediated m6A modification of HIF-1α.
    Yang N; Wang T; Li Q; Han F; Wang Z; Zhu R; Zhou J
    J Cell Physiol; 2021 May; 236(5):3863-3880. PubMed ID: 33305825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The functional roles, cross-talk and clinical implications of m6A modification and circRNA in hepatocellular carcinoma.
    Qin S; Mao Y; Chen X; Xiao J; Qin Y; Zhao L
    Int J Biol Sci; 2021; 17(12):3059-3079. PubMed ID: 34421350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIF-1α-induced expression of m6A reader YTHDF1 drives hypoxia-induced autophagy and malignancy of hepatocellular carcinoma by promoting ATG2A and ATG14 translation.
    Li Q; Ni Y; Zhang L; Jiang R; Xu J; Yang H; Hu Y; Qiu J; Pu L; Tang J; Wang X
    Signal Transduct Target Ther; 2021 Feb; 6(1):76. PubMed ID: 33619246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of N6-methyladenosine readers' genes variation and expression level with pulmonary tuberculosis.
    Li HM; Tang F; Wang LJ; Huang Q; Pan HF; Zhang TP
    Front Public Health; 2022; 10():925303. PubMed ID: 36072379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
    Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
    Front Immunol; 2021; 12():669750. PubMed ID: 34054840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N6-Methyladenosine Reader YTHDF1 Promotes Stemness and Therapeutic Resistance in Hepatocellular Carcinoma by Enhancing NOTCH1 Expression.
    Zhang X; Su T; Wu Y; Cai Y; Wang L; Liang C; Zhou L; Wang S; Li XX; Peng S; Kuang M; Yu J; Xu L
    Cancer Res; 2024 Mar; 84(6):827-840. PubMed ID: 38241695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.